Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rekah Pharmaceutical ProdXTAE:REKA 57 Current Ratio is 1.47 as of Mar. 2026, which is 28% below its 10-year median of 2.05. GuruFocus rates XTAE:REKA with a GF Score™ of 57/100 and a GF Value™ of ₪13.05 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 999 Drug Manufacturers companies, Rekah Pharmaceutical Prod ranks worse than 67.07% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Rekah Pharmaceutical Prod's current ratio for the quarter that ended in Mar. 2026 was 1.47.
Rekah Pharmaceutical Prod has a current ratio of 1.47. It generally indicates good short-term financial strength.
The historical rank and industry rank for Rekah Pharmaceutical Prod's Current Ratio or its related term are showing as below:
XTAE:REKA'
s Current Ratio Range Over the Past 10 Years
Min: 1.43 Med: 2.05 Max: 2.61
Current: 1.47
During the past 13 years, Rekah Pharmaceutical Prod's highest Current Ratio was 2.61. The lowest was 1.43. And the median was 2.05.
XTAE:REKA's Current Ratio is ranked worse than 67.07% of 999
companies
in the Drug Manufacturers industry
Industry Median: 2
vs XTAE:REKA: 1.47
Rekah Pharmaceutical Prod (XTAE:REKA) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Rekah Pharmaceutical Prod Current Ratio Related Terms
Rekah Pharmaceutical Prod Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTAE:REKA vs ZTS, UTHR, VTRS: Current Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Rekah Pharmaceutical Prod's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rekah Pharmaceutical Prod Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rekah Pharmaceutical Prod's Current Ratio distribution charts can be found below:
* The bar in red indicates where Rekah Pharmaceutical Prod's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rekah Pharmaceutical Prod (XTAE:REKA) has a Current Ratio of 1.47 as of Mar. 2026. This is 28% below median its historical median of 2.05. Over the past decade, Rekah Pharmaceutical Prod's Current Ratio has ranged from 1.43 to 2.61. According to the industry distribution chart, Rekah Pharmaceutical Prod ranks #670 out of 999 companies in the Drug Manufacturers industry, placing it in the top 67.1%.
Is Rekah Pharmaceutical Prod's Current Ratio too high?
Rekah Pharmaceutical Prod's current Current Ratio of 1.47 is 28% below median its 10-year median of 2.05. Over the past 10 years, this metric has ranged from a low of 1.43 to a high of 2.61. The Drug Manufacturers industry median Current Ratio is 2.00. Rekah Pharmaceutical Prod's value of 1.47 is 26.5% below this industry median. Based on the distribution chart, Rekah Pharmaceutical Prod ranks #670 out of 999 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Rekah Pharmaceutical Prod has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Rekah Pharmaceutical Prod's Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Rekah Pharmaceutical Prod ranks #670 out of 999 companies for Current Ratio. This places Rekah Pharmaceutical Prod in the lower half of its industry. The industry median Current Ratio is 2.00. Rekah Pharmaceutical Prod's value of 1.47 is 26.5% below this benchmark. Historically, Rekah Pharmaceutical Prod's own Current Ratio has ranged from 1.43 to 2.61 over the past decade. While the company's 10-year median is 2.05 vs. the industry median of 2.00, Rekah Pharmaceutical Prod has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 999 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rekah Pharmaceutical Prod's current Current Ratio of 1.47 is 26.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rekah Pharmaceutical Prod's current Current Ratio is 1.47, which is 28% below median its own 10-year median of 2.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rekah Pharmaceutical Prod stock overvalued right now?
Based on GuruFocus' analysis, Rekah Pharmaceutical Prod (XTAE:REKA) is currently considered Modestly Undervalued. The stock's GF Value™ is ₪13.05, compared to a current price of ₪10.89 — trading 16.6% below its estimated fair value. The current Current Ratio is 1.47, which is 28% below median its 10-year median of 2.05 and 26.5% below the Drug Manufacturers industry median of 2.00. Rekah Pharmaceutical Prod's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Rekah Pharmaceutical Prod (XTAE:REKA), the current Current Ratio is 1.47 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rekah Pharmaceutical Prod (XTAE:REKA) Overvalued in 2026?
Based on GuruFocus' analysis, Rekah Pharmaceutical Prod stock appears to be undervalued.
The current stock price of ₪10.89 is trading 16.6% below its estimated GF Value™ of ₪13.05.
GuruFocus considers Rekah Pharmaceutical Prod to be Modestly Undervalued.
Key valuation signals for XTAE:REKA:
Current Ratio: 1.47 (28% below median its 10-year median of 2.05)
GF Value™: ₪13.05 vs. price of ₪10.89 (16.6% below fair value)
Industry Position: 26.5% below the Drug Manufacturers median (#670 of 999)
No single metric tells the full story. See the XTAE:REKA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rekah Pharmaceutical Prod Ltd is engaged in the manufacturing, importing, marketing, and distribution of pharmaceuticals and cosmetics. It primarily caters to the needs of hospitals, retirement homes, and national medical healthcare services.
57GF Score
Get the complete analysis for XTAE:REKA
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTAE:REKA has been successfully added to your 
